The search for new biomarkers predictive of type 2 diabetes currently constitutes a research avenue in Bioclinical. Total homocysteine remains a preferred target due to its involvement in the occurrence of degenerative complications in type 2 diabetics. The aim of this work was to study hyperhomocysteinemia and other biochemical markers associated with T2D in the Congolese population. This was an analytical case-control study carried out between October 2022 and October 2023. The study population consisted of 150 subjects including 100 T2D patients and 50 control subjects. The main clinical data were collected on a pre-established form. Homocysteine determination was carried out by the sandwich ELISA method. The other biochemical markers were measured by colorimetric enzymatic methods. Hyperhomocysteinemia was present in 27.3% (41/150) of the entire study population. Type 2 diabetics had a frequency of hyperhomocysteinemia of 36% (36/100) and control 10% (5/50) (p = 0.001). The mean hyperhomocysteinemia concentration was 31.9 μmol/l with extremes ranging from 18 to 103 μmol/l. Means of biological markers between diabetics and controls showed a statistically significant difference (p = 0.01). The risk factors associated with this HHcy were: sex (OR = 3.5), age (OR = 9.4), sedentary lifestyle (OR = 3.4) and glycosylated hemoglobin (OR = 12) with a p-value <0.05 respectively. Our results suggest that hyperhomocysteinemia can be considered as a predictive biomarker in the bioclinic of Congolese type 2 diabetic patients.
References
[1]
Saeedi, P., Petersohn, I., Salpea, P., Malanda, B., Karuranga, S., Unwin, N., et al. (2019) Global and Regional Diabetes Prevalence Estimates for 2019 and Projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th Edition. Diabetes Research and Clinical Practice, 157, Article 107843. https://doi.org/10.1016/j.diabres.2019.107843
[2]
Congo Ministry of Health (2013) Integrated National Plan for the Fight against Non-Communicable Diseases in Congo, 2013-2017.
[3]
CDC (2020) National Diabetes Statistics Report 2020. Centers for Disease Control and Prevention, US Department of Health and Human Services, Atlanta, 12-15.
[4]
Ajuluchukwua, J., Oluwatowojua, I., et al. (2011) Plasma Total Homocysteine in Diverse Cardiovascular Diseases in Urban Africans. World Journal of Life Science and Medical Research, 1, 126-132.
[5]
Attia, A., Douki, W., et al. (2005) Homocysteine: Metabolism, Dosage and Implications in Human Pathology. Feuillets de Biologie, 266, 33-42.
[6]
Mtiraoui, N., Ezzidi, I., et al. (2007) MTHFR C677T and A1298C Gene Polymorphisms and Hyperhomocysteinemia as Risk Factors of Diabetic Nephropathy in Type 2 Diabetes Patients. Diabetes Research and Clinical Practice, 75, 99-106. https://doi.org/10.1016/j.diabres.2006.05.018
[7]
Ukinc, K., Ersoz, H.O., et al. (2009) Methyltetrahydrofolate Reductase C677T Gene Mutation and Hyperhomocysteinemia as a Novel Risk Factor for Diabetic Nephropathy. Endocrine, 36, 255-261. https://doi.org/10.1007/s12020-009-9218-7
[8]
Agullo-Ortuno, M.T., Albaladejo, M.D., et al. (2002) Plasmatic Homocysteine Concentration and Its Relationship with Complications Associated with Diabetes Mellitus. ClinicaChimicaActa, 326, 105-112. https://doi.org/10.1016/S0009-8981(02)00287-5
[9]
Mazza, A., Bossone, E., et al. (2005) Reduced Serum Homocysteine Levels in Type 2 Diabetes. Nutrition, Metabolism and Cardiovascular Diseases, 15, 118-124. https://doi.org/10.1016/j.numecd.2004.03.001
[10]
Mabchour, A.E., Agueh, V., et al. (2010) [Determinants and Relationship of homocysteinemia with Cardiometabolic Risk Factors. A Study in Benin, West Africa]. La PresseMédicale, 39, e238-e246. https://doi.org/10.1016/j.lpm.2010.03.024
[11]
Zendjabil, M., Abbou, O.and Chellouai, Z. (2017) [Association between Metabolic Syndrome and Hyperhomocysteinemia in an Algerian Population]. AnnalesPharmaceutiquesFrancaises, 75, 54-58. https://doi.org/10.1016/j.pharma.2016.05.001
[12]
Onomhaguan, E.M. and Odunayo, O.E. (2012) Elevated Plasma Homocysteine in Type 2 Diabetes Mellitus: A Risk Factor for Cardiovascular Diseases. Pan African Medical Journal, 12, Article 48.
[13]
Cisse, F., Diallo, F., Diatta, A., et al. (2015) Hyperhomocysteinemia and Type 2 Diabetes. Revue du CAMES: Science de la santé, 3, 9-12.
[14]
Weiss, N., Keller, C., et al. (2002) Endothelial Dysfunction and Atherothrombosis in Mild Hyperhomocysteinemia. Vascular Medicine, 7, 227-239. https://doi.org/10.1191/1358863x02vm428ra
[15]
Drzewoski, J., Czupryniak, L., Chwatko, G. and Bald, E. (2000) Hyperhomocysteinemia in Poorly Controlled Type 2 Diabetes Patients. Diabetes, Nutrition & Metabolism, 13, 312-324.
[16]
Amouzou, E.K., Chabi, N.W., et al. (2004) High Prevalence of Hyperhomocysteinemia Associated with Folate Deficiency and the 677C-T Mutation of the Gene Encoding Methylentetrahydrofolate Reductase in Coastal West Africa. The American Journal of Clinical Nutrition, 79, 619-624. https://doi.org/10.1093/ajcn/79.4.619
[17]
Belkhair, J., Sebbani, M., Lachgar, F., Baizri, H., Amine, M. and Chellak, S. (2019) [Hyperhomocysteinemia in a Type 2 Diabetic Population: Prevalence and Its Association with Clinico-Biological Parameters]. Metabolic Disease Medicine, 13, 556-560. https://doi.org/10.1016/S1957-2557(19)30172-5
[18]
Lakhoua, Y., Khiairi, K., et al. (2013) [Metabolic Syndrome and Homocysteine]. Diabetes & Metabolism, 39, A107. https://doi.org/10.1016/S1262-3636(13)72080-9
[19]
Chellak, S., Bigaillon, C., et al. (2005) [Correlation Results between Plasma Homocysteine, Metabolic Syndrome Components and Cardiovascular Risk Markers in 2045 French Military Subjects: EPIMIL Cohort]. Immuno-Analyse & BiologieSpécialisée, 20, 169-172. https://doi.org/10.1016/j.immbio.2005.03.002
[20]
Mello, A.L., Cunha, S.F., et al. (2012) Evaluation of Plasma Homocysteine Level According to the C677T and A128C Polymorphism of the Enzyme MTHFR in Type 2 Diabetic Adults. ArquivosBrasileiros de Endocrinologia & Metabologia, 56, 429-434. https://doi.org/10.1590/S0004-27302012000700004
[21]
Djohan, Y.F., Koffi, K.G., et al. (2013) [Interest in the Dosage of Homocysteine, Vitamin B12 and Folic Acid in the Course of Cardiovascular Diseases in Ivory Coast]. Revue du CAMES: Science de la Santé, 1, 2.
[22]
Damelan, K., Kom, A., et al. (2010) [Hyperhomocysteinemia among Ischemic Stroke Victims in the Teaching Hospital of Lomé]. Annales de Biologie Clinique, 68, 669-673.
[23]
Chadli-Chaieb, M., Marmouch, H., Mtiraoui, N., Mahjoub, T. and Chaieb, L. (2008) [C677T and A1298C Polymorphism of the Methylene-Tetrahydrofolate Reductase (MTHFR) Gene and Cardiovascular Risk in Type 2 Diabetics]. Diabetes & Metabolism, 34, H55. https://doi.org/10.1016/S1262-3636(08)72957-4
[24]
Grunitzky, E., Balogou, A., et al. (2008) Homocysteineemia and Ischmeic Cerebral Vascular Accidents at the University Hospital Campus of Lomé. American Journal of Nursing Science, 27, 3-6.
[25]
Ferjani, W., Bouzid, K., et al. (2011) [Relationship between Blood Homocysteine and Creatinine in Subjects with Metabolic Syndrome and Association between Hyperhomocysteinemia and Metabolic Syndrome]. Immuno-Analysis and Specialized Biology, 26, 244-249. https://doi.org/10.1016/j.immbio.2011.10.004
[26]
Diakoumopoulou, E., Tentolouris, N., et al. (2005) Plasma Homocysteine Levels in Patients with Type 2 Diabetes in a Mediterranean Population: Relationship with Nutritional and Other Factors. Nutrition, Metabolism and Cardiovascular Diseases, 15, 109-117. https://doi.org/10.1016/j.numecd.2004.01.001
[27]
Krauss, R.M. (2004) Lipids and Lipoproteins in Patients with Type 2 Diabetes. Diabetes Care, 27, 1496-1504. https://doi.org/10.2337/diacare.27.6.1496
[28]
Ndrepepa, G., Kastrati, A., et al. (2008) Circulating Homocysteine Levels in Patients with Type 2 Diabetes Mellitus. Nutrition, Metabolism & Cardiovascular Diseases, 18, 66-73. https://doi.org/10.1016/j.numecd.2006.03.007
[29]
Otmane, A., Makrelouf, M., et al. (2007) [Total Homocysteine Levels in a Cohort of Type 2 Diabetics]. Revue Francophone des Laboratoires, 2007, 21-24. https://doi.org/10.1016/S1773-035X(07)80418-7
[30]
Glew, R.H., Okolie, H., et al. (2004) Serum Lipid Profiles and Homocysteine Levels in Adults with Stroke or Myocardial Infarction in the Town of Gombe in Northern Nigeria. Journal of Health, Population, and Nutrition, 22, 341-347.
